BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
3/26/2025 10:16:39 AM | Browse: 10 | Download: 55
 |
Received |
|
2024-10-11 12:04 |
|
Peer-Review Started |
|
2024-10-11 12:04 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2024-10-30 08:40 |
|
Revised |
|
2024-11-13 10:25 |
|
Second Decision |
|
2025-01-15 02:40 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2025-01-15 11:25 |
|
Articles in Press |
|
2025-01-15 11:25 |
|
Publication Fee Transferred |
|
2024-11-15 04:30 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2025-02-06 01:53 |
|
Publish the Manuscript Online |
|
2025-03-26 10:16 |
| ISSN |
2218-4333 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Retrospective Study |
| Article Title |
Combination of anlotinib and albumin-bound paclitaxel in 2nd line and above treatment of advanced gastric cancer: A retrospective study
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Wen-Ming Liu, Yi-Rui Liu, Yi Peng, Jing Tang and Xiao-Bing Li |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| Natural Science Foundation of Hubei Province |
No. 2019CFC929 |
|
| Corresponding Author |
Xiao-Bing Li, Assistant Professor, MD, PhD, Department of Thoracic Oncology, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, No. 116 South Zhuodaoquan Road, Hongshan District, Wuhan 430079, Hubei Province, China. lixiaobing0629@126.com |
| Key Words |
Advanced gastric cancer; Drug combination; Albumin-bound paclitaxel; Anlotinib; Cohort study |
| Core Tip |
The second-line or above treatment for advanced gastric cancer lacks effective therapeutic models. The results of this study indicate that the small molecule vascular endothelial growth factor inhibitor anlotinib combined with albumin-bound paclitaxel has significantly improved efficacy in gastric cancer treatment, and the toxic side effects are manageable. Further analysis showed that patients who experience hypertension, proteinuria, and hand-foot syndrome during treatment derive greater benefit from this regimen. The mechanism of this combination treatment may involve the depletion of immune suppression to activate the immune system, thereby exerting a synergistic anti-tumor effect, demonstrating the potential of this regimen for clinical application. |
| Publish Date |
2025-03-26 10:16 |
| Citation |
<p>Liu WM, Liu YR, Peng Y, Tang J, Li XB. Combination of anlotinib and albumin-bound paclitaxel in 2nd line and above treatment of advanced gastric cancer: A retrospective study. <i>World J Clin Oncol</i> 2025; 16(4): 102199</p> |
| URL |
https://www.wjgnet.com/2218-4333/full/v16/i4/102199.htm |
| DOI |
https://dx.doi.org/10.5306/wjco.v16.i4.102199 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
